# Jiwoong Chun

> Jiwoong Chun is a Series B investor at KTB Network backing Health Care and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KTB Network](https://shizune.co/investors/profile/ktb-network-2)
- Total investments: 2
- Last investment: Jul 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jiwoong-chun-a35138b1

Jiwoong Chun is a Series B investor at KTB Network focused on Health Care and Therapeutics. Jiwoong Chun is the Board Member of Illimis Therapeutics. Jiwoong Chun attended Seoul National University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Therapeutics | 2 | 100% |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |
| Pharmaceutical | 1 | 50% |

6 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Taiwan | 1 | 50% |
| South Korea | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Illimis Therapeutics | Illimis Therapeutics is a platform-based biotech company that develops a chimeric fusion protein platform for neurodegenerative diseases. The company's proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved inregulating inflammation and immune responses. | $41.9M | Series B | Jul 14, 2025 |  |
| APRINOIA Therapeutics | APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $11.1M | Series B | Jan 16, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [Aju IB Investment](https://shizune.co/investors/profile/aju-ib-investment) — VC Fund, 1 deal together
- [A Ventures](https://shizune.co/investors/profile/a-ventures-88a4) — VC Fund, 1 deal together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 1 deal together
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 1 deal together
- [DCI Partners](https://shizune.co/investors/profile/dci-partners) — VC Fund, 1 deal together
- [DSC Investment](https://shizune.co/investors/profile/dsc-investment) — VC Fund, 1 deal together

## About KTB Network

VC Fund · Seongnam, South Korea

Korea Technology Development Company, a government-funded investment vehicle specializing in technology-related investment opportunities, KTB Financial Group(“KTB”) has since grown into a comprehensive financial group offering a wide range of financial services, including securities, asset management, venture capital, and private equity.KTB alsohas expanded our global network by actively entering overseas markets includes the United States, China, and Thailand.

5 contacts available at KTB Network.

| Name | Title | Profile |
| --- | --- | --- |
| HoChan Lee | Managing Director | https://shizune.co/investors/profile/hochan-lee |
| Ji Eun Lee | Team Manager | https://shizune.co/investors/profile/ji-eun-lee-5250 |
| Jinho Shin | CEO | https://shizune.co/investors/profile/jinho-shin-16df |
| Jiwoong Chun | Investment leader | https://shizune.co/investors/profile/jiwoong-chun-1138 |
| Kevin Kuk-Hyun Kyung | Team Manager | https://shizune.co/investors/profile/kevin-kuk-hyun-kyung |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Jiwoong Chun invest in?

Jiwoong Chun invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jiwoong Chun last invest?

The most recent investment recorded for Jiwoong Chun closed in Jul 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co